leading global biopharmaceutical company dedicated to improving the health and well-being of patients.

We have presented a new paradigm to the global biologics market with the launch of the world's first monoclonal antibody biosimilar.

will continue to pursue its goal in promoting the health and well-being of patients.

Vision

We are working to create a healthier tomorrow where no patients are left untreated

Will continue to push its scientific and medical boundaries to help patients return to their everyday lives in full wellness.

Vision

We are working to create a healthier tomorrow where no patients are left untreated

Will continue to push its scientific and medical boundaries to help patients return to their everyday lives in full wellness.

At a Glance

000
countries

Leader in Biotechnology Research

Celltrion's R&D personnel with masters and doctoral degrees account for around 33% of total employees. At the Global R&D Center, our R&D specialists are striving to develop new biosimilars as well as various new drugs and drug delivery platforms. In addition, Celltrion invests about 20% of its revenue every year in R&D, securing the foundation for continuous growth.

000
%

Expertise in Biologics Development Recognized by Regulators Across the World

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

000
%

World Class Production Capabilities and Quality Control System

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.